Skip to main content
Premium Trial:

Request an Annual Quote

Shane Grey, Judy Bruner, James Rothman

Premium

Shane Grey has been appointed to the scientific advisory board of Squolamie, Wash.-based CombiMatrix, a subsidiary of Newport Beach, Calif.-based Acacia Research. Grey, an assistant professor in surgery at Harvard Medical School, holds a PhD in immunology and pathology from Monash University in Australia. He did postdoctoral research in human immunology, gene therapy and transplantation at the Sandoz Center for Immunobiology in Boston. He will move his research this year to the Garvan Institute of Medical Research in Sydney, Australia.

 

Judy Bruner has joined Ciphergen’s board of directors and will become the chairman of the company’s audit committee. Bruner has been the senior vice president and chief financial officer of Milpitas, Calif.-based Palm since 1999. Previously, she was vice president, finance and corporate controller at 3Com. Bruner holds a BA in economics from the University of California, Los Angeles and an MBA from Santa Clara University.

 

James Rothman has been named chief scientific adviser of Amersham PLC, Amersham Biosciences’ parent company. Rothman will sit on Amersham’s portfolio committee, which is responsible for guiding the company’s growth.

Rothman is currently chairman of the cellular biochemistry and biophysics program at Memorial Sloan-Kettering Cancer Center in New York, and has recently been appointed to the department of physiology at Columbia University’s College of Physicians and Surgeons, where he will head up a new center for chemical biology. Before joining Memorial Sloan-Kettering, Rothman was a professor of molecular biology at Princeton University between 1988 and 1991.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.